Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyotrophic Lateral Sclerosis
Intrathecal BDNF doesn't improve autonomic function
August 26th, 2005
Intrathecal BDNF treatment does not provide significant benefits to amyotrophic lateral sclerosis (ALS) patients. In a "pilot study," neurologists in Germany examined "the effects of intrathecally administered brain derived neurotrophic factor (BDNF) on autonomic functions in patients with ALS." "A battery of autonomic sympathetic and parasympathetic tests was performed at baseline and after 9 months of treatment in 10 ALS patients participating in a double-blind placebo-controlled phase II/III study of intrathecally administered BDNF," explained M. Beck and coauthors at the University of Wurzburg. "Results of patients treated with BDNF (25 or 150...
Source: Drug Week (2005-08-26)
|
